secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001493152-24-047146
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Mira Pharmaceuticals appoints Matthew Pratt Whalen to board, replacing Michael Jerman
--------------------------------------------------------------------------------

- Michael Jerman resigned as director and Audit Committee Chair effective Nov 18, 2024, not due to any disagreement.
- Matthew Pratt Whalen appointed as director and Audit Committee Chair effective same day.
- Whalen is a CPA with over 20 years experience, currently CFO of Power Digital Marketing since May 2021.
- Whalen also serves as director on the board of Telmoir Pharmaceuticals (NASDAQ: TELO) since August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224047146/0001493152-24-047146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224047146/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-047146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer